Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.

Abstract: The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.

Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim 1, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: An inlet guide for facilitating distribution of optical fibers into at least one duct is provided. The inlet guide includes a first portion, a second portion, a first end, a second end, a head, and a main body. The first portion includes a first opposing surface. The second portion includes a second opposing surface and is separable from the first portion. The head is disposed at the first end and comprises an outlet port. The main body is disposed at the second end. The first portion and the second portion cooperate to define a plurality of passageways for the optical fibers. The plurality of passageways extends between the first end and the second end.

Abstract: A communications cable that has a core that includes a dielectric separator. The separator has a spline that extends longitudinally in the core, thereby dividing the core into at least two quadrants. The separator also has at least one compartment. At least one pair of twisted insulated conductors is received in at least one of the quadrants and at least one optical fiber is received in the compartment of the dielectric separator. An outer jacket substantially surrounds the core.

Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim 1, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: An inlet guide for facilitating distribution of optical fibers into at least one duct is provided. The inlet guide includes a first portion, a second portion, a first end, a second end, a head, and a main body. The first portion includes a first opposing surface. The second portion includes a second opposing surface and is separable from the first portion. The head is disposed at the first end and comprises an outlet port. The main body is disposed at the second end. The first portion and the second portion cooperate to define a plurality of passageways for the optical fibers. The plurality of passageways extends between the first end and the second end.

Abstract: A communications cable that has a core that includes a dielectric separator. The separator has a spline that extends longitudinally in the core, thereby dividing the core into at least two quadrants. The separator also has at least one compartment. At least one pair of twisted insulated conductors is received in at least one of the quadrants and at least one optical fiber is received in the compartment of the dielectric separator. An outer jacket substantially surrounds the core.

Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.